Talis Biomedical Corporation Common Stock
TLIS
TLIS: Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
moreShow TLIS Financials
Recent trades of TLIS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TLIS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Optical reaction well for assay device Apr. 25, 2023
-
Patent Title: Polynucleotides for the amplification and detection of chlamydia trachomatis May. 10, 2022
-
Patent Title: Polynucleotides for amplification and detection of sars-cov-2 Jun. 29, 2021
-
Patent Title: Rotary valve May. 18, 2021
-
Patent Title: Diagnostic system May. 18, 2021
-
Patent Title: Polynucleotides for the amplification and detection of Mar. 23, 2021
-
Patent Title: Vented converging capillary biological sample port and reservoir Jan. 26, 2021
-
Patent Title: Diagnostic system Nov. 03, 2020
-
Patent Title: Cartridge Jun. 09, 2020
-
Patent Title: Analysis instrument Apr. 14, 2020
-
Patent Title: Rotary valve Jan. 07, 2020
-
Patent Title: Polynucleotides for the amplification and detection of Oct. 22, 2019
-
Patent Title: Sample preparation module with stepwise pressurization mechanism Apr. 09, 2019
-
Patent Title: Reaction well for assay device Aug. 14, 2018
Federal grants, loans, and purchases
Followers on TLIS's company Twitter account
Number of mentions of TLIS in WallStreetBets Daily Discussion
Recent insights relating to TLIS
Recent picks made for TLIS stock on CNBC
ETFs with the largest estimated holdings in TLIS
Flights by private jets registered to TLIS